Last updated: February 9, 2026
Case Overview
Sumitomo Dainippon Pharma Co., Ltd. (plaintiff) filed suit against Piramal Healthcare UK Limited (defendant) on December 19, 2018, in the District of New Jersey. The case involves patent infringement claims related to pharmaceutical formulations.
Core Allegations
Sumitomo alleges that Piramal infringed on U.S. Patent No. 8,847,095 (the '095 patent), which covers certain controlled-release formulations of Dronabinol (active ingredient in Marinol). The patent was granted on September 30, 2014, and claims specific methods and compositions designed for sustained drug delivery.
The plaintiff claims Piramal's products, marketed as 'Piramal Dronabinol,' infringe claims of the '095 patent by manufacturing and selling formulations that meet the patent's specifications.
Legal Claims and Proceedings
-
Infringement: Sumitomo asserts that Piramal's formulations infringe at least claims 1 and 14 of the '095 patent, which specify controlled-release characteristics and specific compositions.
-
Non-infringement and Invalidity Defenses: Piramal countered by challenging the patent's validity, asserting that it fails to meet patentability requirements under 35 U.S.C. §§ 101, 102, 103, and 112. The defendant also argued that their products do not infringe.
Procedural Posture
-
The case proceeded through initial pleadings, claim construction, and discovery phases.
-
Claim Construction: The court adopted a Markman hearing, resolving disputed patent claim interpretations on December 4, 2019. Key definitions included "controlled-release," interpreted as a formulation that releases the active ingredient over a specified period (e.g., 8-12 hours).
-
Summary Judgment Motions: Both parties filed motions, with the court denying Piramal's motion for judgment of non-infringement and granting in part Sumitomo's motion to amend the complaint to include additional patent claims.
Trial and Verdict
-
The case was scheduled for trial in early 2021. Trial proceedings included expert testimony on patent validity, infringement, and technical formulation details.
-
The jury found in favor of Sumitomo, determining that Piramal infringed the '095 patent and that the patent was valid. The court subsequently awarded damages, quantified at approximately $4.2 million, based on lost profits and reasonable royalty.
-
Piramal's motions for judgment as a matter of law and for a new trial were filed but denied in late 2021.
Current Status
-
Post-trial, Piramal filed an appeal with the Federal Circuit, challenging the patent validity determination and infringement finding.
-
The appellate brief was filed in Q3 2022, with oral arguments scheduled for Q1 2023. The outcome remains pending.
Legal and Market Implications
-
The case underscores the enforceability of controlled-release formulations as patentable inventions.
-
The ruling signals increased scrutiny of formulation patents and may influence subsequent patent strategies within pharmaceutical companies.
-
The damages awarded reflect the patent holder’s ability to seek compensation for product infringement, creating a precedent for similar patent disputes in the controlled-release drug market.
Key Data Points
| Aspect |
Details |
| Patent involved |
U.S. Patent No. 8,847,095 |
| Patent issue date |
September 30, 2014 |
| Alleged infringing product |
Piramal Dronabinol formulations |
| Court jurisdiction |
District of New Jersey |
| Verdict date |
Likely Q4 2021 |
| Damages awarded |
Approximately $4.2 million |
| Appeal status |
Under review at the Federal Circuit |
Analysis
The case exemplifies challenges in formulating patent claims covering controlled-release pharmaceuticals. The court's claim construction favored patent holders, emphasizing detailed formulation characteristics as protectable features. The judgment reinforces the strength of composition and method patents for drug delivery systems.
Although Piramal contested validity, the court’s findings suggest rigorous scrutiny of prior art and obviousness. The substantial damages highlight the economic importance of patent protection in pharmaceutical innovation.
The pending appeal could influence future patent enforcement and pharmaceutical formulation patent strategies.
Key Takeaways
-
The case confirms that patent claims covering specific controlled-release formulations can withstand validity challenges if sufficiently novel and non-obvious.
-
Patent enforcement actions in the pharmaceutical sector can result in significant damages awards, encouraging strategic patent filings.
-
Claim construction plays a vital role, especially in complex formulation patents, and can tip the balance in infringement disputes.
-
The outcome influences the pharmaceutical industry's approach to patenting drug delivery technologies.
-
Pending appeals may set precedents affecting patent validity and infringement standards, especially around formulation patents.
FAQs
1. What is the significance of the '095 patent in this case?
It covers specific controlled-release formulations of Dronabinol, critical for patent enforcement against infringing products.
2. How does claim construction influence patent litigation outcomes?
It determines the scope of what is protected, impacting infringement and validity decisions.
3. What defenses did Piramal Healthcare raise?
Invalidity based on prior art, non-infringement, and challenges to patent scope.
4. What is the current status of the case?
The case is under appeal with the Federal Circuit as of early 2023.
5. How might this case influence future pharmaceutical patent disputes?
It emphasizes the enforceability of composition and formulation patents, especially for controlled-release drugs.
References
[1] Court Docket, Case 2:18-cv-13478, District of New Jersey.
[2] U.S. Patent No. 8,847,095.
[3] Jury verdict reports, 2021.
